AllSci News
Enliven Therapeutics upsizes USD 400m offering to 60% above target
Burlingame, California-based Enliven Therapeutics, Inc. (Nasdaq: ELVN) announced the pricing of an upsized underwritten public offering of common stock and...
Gan & Lee's posts competitive Phase III readouts for bi-weekly GLP-1 contender bofanglutide, basal insulin ludefen
China-based Gan & Lee Pharmaceuticals (603087.SH) reported simultaneous positive Phase III readouts for two metabolic disease candidates on June 12,...
Otsuka completes USD 1.2b acquisition of Transcend Therapeutics for PTSD neuroplastogen
Otsuka Pharmaceutical has completed its acquisition of Transcend Therapeutics, with New York-based Transcend now a wholly owned subsidiary of Otsuka...
Adial Pharma buys out Stanford Uni spinout Azora, holds USD 64m financing round
Glen Allen, Virginia-based Adial Pharmaceuticals (Nasdaq: ADIL) has acquired Azora Therapeutics, a Stanford University spinout developing oral...
Camurus receives second manufacturing-linked CRL from FDA for Oclaiz acromegaly drug
Sweden-based Camurus AB (Nasdaq Stockholm: CAMX) announced on that the US FDA has issued a Complete Response Letter (CRL) for a New…
Novartis displays Rhapsido's Phase III efficacy across chronic urticaria subtypes at EAACI
Remibrutinib (Rhapsido) has become the first therapy to demonstrate statistically significant efficacy across all three major subtypes of chronic inducible...
Summit thinks twice about USD 200m public offering citing adverse market conditions
Summit Therapeutics Inc. (Nasdaq: SMMT) disclosed on June 12, 2026 that it had withdrawn a previously announced proposed underwritten public offering,...
Jazz faces uncertainty over Zepzelca's accelerated approval after Phase III LAGOON failure
The Phase III LAGOON trial has failed to confirm the second-line benefit of lurbinectedin (Zepzelca) in relapsed small cell lung cancer, a result that puts...
Novartis's FAP-targeting radioligand enters Phase I for solid tumors
Novartis has initiated a first-in-human Phase I trial of [⁶⁸Ga]Ga-DFC413 (JFI447), a Gallium-68-labeled radioligand designed to image fibroblast activation...
MediciNova receives US patent for ibudilast glioblastoma combination therapy through 2042
La Jolla, California-based MediciNova (Nasdaq: MNOV) received a Notice of Allowance from the US Patent and Trademark Office for a method-of-treatment patent…
PeptiDream's CLDN18.2 radiopharmaceutical enters first-in-human study in gastric cancer
Japan-based PeptiDream Inc. (Tokyo Stock Exchange: 4587) has announced the first patient dosing in a first-in-human radiopharmaceutical clinical trial of...
China’s NMPA approves Akeso’s IL-17A gumokimab for moderate-to-severe plaque psoriasis
China’s NMPA approves Akeso’s gumokimab (AK111) for moderate-to-severe plaque psoriasis, adding a domestically developed anti-IL-17 monoclonal antibody to a class previously dominated…
UK approves Novo Nordisk’s Wegovy pill for weight management in adults with obesity
Novo Nordisk’s Wegovy pill (semaglutide tablets 25 mg) has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for…
Cognision research points to baseline EEG signature guiding to hidden responder groups in ketamine challenge studies
Researchers at Louisville, Kentucky-based Cognision (Nasdaq: not listed), working through the EEG/ERP Biomarker Qualification Consortium, report that an...
Adlai Nortye's PD-L1, CD86, and LAG-3 tri-specific fusion protein enters Phase I testing
Nasdaq-listed Adlai Nortye Biopharma Co., Ltd. (Nasdaq: ANL) has initiated a first-in-human clinical trial of AN8025, a tri-specific antibody fusion protein...
The AllSci Brief
Free, systematic R&D and deal news. Daily.